



# Bullous Pemphigoid (BP) Clinical Trial

Principal Investigator: Victoria Werth

Current drug trial

Phase 2 RCT:  
**Dupilumab** (anti IL-4/IL-13)

Randomization design

All patients will start **prednisone** to control disease

**1:1** randomization  
Placebo vs. 600 mg loading → 300 mg  
SC injection Q2W  
NO placebo crossover

Inclusion criteria

Diagnosis of BP  
Karnofsky Performance  $\geq$  50%  
BPDAI  $\geq$  24

Exclusion criteria

Pemphigoid other than BP  
Contraindication to systemic corticosteroids

If your patient may be eligible, email [penndermautoimmune@penmedicine.upenn.edu](mailto:penndermautoimmune@penmedicine.upenn.edu) for a screening appointment with Dr. Werth